Doctors choose a liver cancer immunotherapy regimen by weighing the expected cancer control against liver function, bleeding risk, and immune-related risks. For patients who need systemic treatment, the main choices include immunotherapy with an anti-angiogenic drug, dual immunotherapy, or—in selected cases—a single immune drug. Previous treatment, daily activity, and the goal of treatment help determine which option fits.[1]
A recent digestive tract bleed may make a bevacizumab-containing regimen unsuitable. Active autoimmune disease or a liver transplant may limit checkpoint immunotherapy itself. Poor liver function can restrict both approaches.
This article covers hepatocellular carcinoma (HCC). Bile duct cancer and cancers that spread to the liver require different treatment plans.
What Changes the Choice of Treatment
| Factor | What doctors assess | How it affects the plan |
|---|---|---|
| Cancer stage | Tumor number and size, blood vessel involvement, spread outside the liver, and whether surgery is possible. | Surgery, ablation, or transplantation may take priority. Unresectable or metastatic disease often requires systemic treatment. |
| Liver function | Child-Pugh A: 5–6 points; B: 7–9; C: 10–15. | Most major combination trials enrolled class A patients. Class B requires careful selection; class C generally precludes routine systemic cancer treatment. |
| Daily activity | ECOG 0–1 means full activity or mild restrictions. Higher scores reflect greater limits on activity and self-care. | Most major trials enrolled patients with scores of 0–1. For higher scores, doctors investigate whether the decline comes from cancer, liver disease, or a treatable problem. |
| Bleeding risk | Recent bleeding, enlarged veins in the esophagus or stomach, blood pressure, urine protein, and wound healing. | These findings may delay or rule out some drugs that block blood vessel growth. |
| Immune-related history | Autoimmune disease, organ transplantation, and previous serious reactions to immunotherapy. | Checkpoint drugs may worsen autoimmune disease or cause transplant rejection. |
| Previous treatment | Drug names, response, duration of benefit, and reasons for stopping. | Progression and severe side effects lead to different next-treatment decisions. |
Child-Pugh scoring includes bilirubin, albumin, clotting results, abdominal fluid buildup, and brain symptoms caused by liver disease. Normal liver enzymes alone do not show that treatment is safe. Within class B, uncontrolled fluid buildup or worsening liver function can further limit the options.[2]
How the Main Regimens Differ
| Approach | Examples | Selection concerns |
|---|---|---|
| Immunotherapy plus an anti-angiogenic drug | Atezolizumab plus bevacizumab; sintilimab plus a bevacizumab biosimilar; camrelizumab plus apatinib. | Bleeding, uncontrolled blood pressure, significant urine protein, and unhealed wounds. |
| Dual immunotherapy | Nivolumab plus ipilimumab; durvalumab plus tremelimumab. | Immune-related inflammation, including hepatitis and colitis, and the patient’s autoimmune or transplant history. |
| Single-drug immunotherapy | Tislelizumab or other agents in defined treatment settings. | Local approval, previous drugs, and evidence for that treatment line. Frailty alone does not establish suitability. |
These examples span different national treatment guidelines. Approval and insurance coverage must be checked for the country and treatment line. China’s 2026 guideline includes several of these combinations as first-line options.[3]
Before bevacizumab, doctors generally arrange an upper endoscopy to assess enlarged veins that could bleed. High-risk veins may need banding or preventive medication first. Switching to another anti-angiogenic drug does not automatically remove the bleeding risk.[4]
The immunotherapy approach also matters when comparing proposals: the checkpoint drugs above are different from NK-cell therapy. Their survival results cannot be transferred to an NK-cell infusion.
Hepatitis B and Previous Side Effects
Chinese guidelines recommend antiviral treatment for HCC patients who are hepatitis B surface antigen positive, even when HBV DNA is undetectable. Antiviral treatment and monitoring continue alongside cancer care.[5]
If liver tests worsen, doctors need to distinguish hepatitis B activity from immune-related hepatitis, bile duct blockage, cancer progression, and other drug effects. The cause determines whether treatment should continue, pause, or change.
A previous severe immune reaction can limit further immunotherapy. If the cancer progressed instead, doctors review which drugs remain reasonable. The best sequence after an immunotherapy combination is still not firmly established by randomized trials.[6]
What Trial Results Can Tell You
CheckMate-9DW enrolled 668 patients with unresectable or metastatic HCC, Child-Pugh A liver function, and ECOG scores of 0–1. None had received systemic treatment for advanced disease.
| Result | Nivolumab plus ipilimumab | Lenvatinib or sorafenib |
|---|---|---|
| Objective response rate | 36.1% | 13.2% |
| Median overall survival | 23.7 months | 20.6 months |
Responses were assessed using RECIST 1.1 criteria by blinded independent central review. The FDA reported these results when approving the combination for first-line HCC treatment in April 2025.[7]
The 36.1% response rate is not a cure rate. The 23.7-month median is not an individual life expectancy. These results describe one regimen in a selected trial population—not all liver cancer immunotherapy.
Separate trials include different patients and follow-up treatments. Their survival figures cannot reliably rank one regimen above another.
Tests Before Treatment
- Imaging: Contrast-enhanced liver CT or MRI, earlier scans for comparison, and imaging of other sites when needed.
- Blood tests: Blood count, liver and kidney function, albumin, bilirubin, clotting tests, AFP, hepatitis tests, and thyroid function.
- Regimen-specific checks: Blood pressure, urine protein, endoscopy, and further heart or lung assessment when indicated.
- Medication review: Previous cancer drugs, antivirals, blood thinners, steroids, other immune-suppressing drugs, and supplements.
Most commonly used HCC immunotherapy combinations do not require a positive PD-L1 result or broad genetic testing. MSI/MMR testing may help identify a specific treatment option or trial, but it is not a routine prerequisite for these combinations.[8]
For a consultation in Japan, confirm which reports need translation and whether original scan files are required. The medical records policy explains how records submitted for coordination may be used and shared.
When the Plan Changes
The first contrast-enhanced CT or MRI may be scheduled around 6–12 weeks after treatment begins. This is not a fixed interval for every regimen. Worsening symptoms or assessment for surgery may require an earlier review.
- Stable disease: Treatment may remain worthwhile without major shrinkage. One AFP increase alone does not establish failure.
- Growth on scans: Doctors assess true progression. Pseudoprogression is uncommon in HCC and should not be assumed.
- Declining liver function: New jaundice or increasing abdominal fluid requires investigation before further treatment.
- Serious side effects: A drug may need to pause or stop. Restarting depends on the organ affected and the severity of the reaction.
Treatment duration varies by regimen. Some courses continue until progression or unacceptable toxicity; others have a specified limit. Neither normal AFP nor one improved scan is enough to decide when to stop.[9]
Symptoms That Need Prompt Care
Contact the treatment team the same day for persistent diarrhea, a new cough or mild breathlessness, jaundice, marked dizziness, unusual weakness, or a widespread rash. Immune-related side effects can also begin after treatment stops.[10]
Vomiting blood, black tar-like stools, severe breathing difficulty, chest pain, fainting, or confusion require immediate medical care. Give the clinician the drug names and last treatment date. Do not start steroids on your own.
Surgery and Postoperative Treatment
If the aim is to make surgery possible, agree on surgical review points before treatment starts. The surgeon must assess blood vessel involvement, disease outside the liver, remaining liver volume, and liver function—not just shrinkage.
Postoperative treatment needs separate evidence. Longer follow-up in IMbrave050 did not sustain the early recurrence-free survival benefit of atezolizumab plus bevacizumab. The study does not support routine use of that combination after surgery or ablation. Other postoperative regimens require their own evidence.[11]
Questions for Your Appointment
- What are my cancer stage, Child-Pugh class, and ECOG score?
- Which findings support this regimen, and which risks limit the alternatives?
- When is my first scan, what will treatment cost, and who handles side effects?
This article provides patient information and does not replace an individual medical assessment.